CJC-1295 and TB-500

Mentioned together

Named together in the same review articles, but never tested together. We say that plainly here, and show why researchers list them side by side.

How the two mechanisms relate

Neutral. TB-500, a thymosin beta-4 fragment, and CJC-1295, a GHRH analogue, are named together in research reviews but act on unrelated pathways, with no combined data recorded here.

This part is our reading of the mechanism. The grade above is what the published record shows.

The compounds

CJC-1295

A long-acting GHRH analogue studied for growth-hormone release. Two early human trials measured hormone levels; no human study here reports a functional outcome.

Full profile, dosing and safety →

TB-500

A short fragment of thymosin beta-4. Almost all outcome data are animal or laboratory, and the one human randomized trial used the full parent peptide, not the fragment.

Full profile, dosing and safety →

Check these in the interaction tool →